Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 8 , ISSUE 2 ( July-December, 2018 ) > List of Articles


Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country

Ahmed L Moben, Faiz A Khondaker, Masuda Mohsena, Masuda Begum, Md. A Islam, Md. A Rahim, Md. A Alam, Md. Sakirul I Khan, Md. Z Huq, Swati Munshi, Ashraful Hoque, Sheikh A Haque

Keywords : Ascites, Decompensated, Liver cirrhosis, Stem cell

Citation Information : Moben AL, Khondaker FA, Mohsena M, Begum M, Islam MA, Rahim MA, Alam MA, Khan MS, Huq MZ, Munshi S, Hoque A, Haque SA. Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country. Euroasian J Hepatogastroenterol 2018; 8 (2):121-125.

DOI: 10.5005/jp-journals-10018-1277

License: CC BY-NC 4.0

Published Online: 01-01-2019

Copyright Statement:  Copyright © 2018; The Author(s).


Aims and objectives: To assess the safety and efficacy of stem cell therapy in patients with cirrhosis of the liver (LC) in the context of developing country with limited facilities for cell-based therapy and advanced technologies. Materials and methods: A total of 34 patients received granulocyte colony-stimulating factor at a dose of 30 IU, daily for 2 to 11 days to upregulate the numbers of white blood cells and stem cells. Subsequently, stem cells were isolated from the peripheral blood of LC patients in a closed chamber using a harvesting machine. Variable amounts of autologous stem cells were injected to LC patients for once. The patients were followed for 3 months and various factors related to safety and parameters of efficacy were analyzed in this interim report. Results: Out of 34 patients available for final analysis, 3 months after the start of stem therapy, 4 patients died within this period. There was no significant alteration in biochemical parameters due to stem cell therapy, and patients also did not develop any features of acute liver failure indicating that short-term safety parameters of stem cell therapy may be acceptable. Stem cell therapy had a dominant effect on ascites of in this cohort. Although 24 of 34 patients had ascites at the start of therapy, ascites were found in 11 patients after one month and only 4 patients had ascites after 3 months. The positive role of stem cell therapy on ascites in LC patients may be attributed, even in part, to increased serum levels of albumin after therapy compared to basal levels (p <0.001). Conclusion: This first study about stem cell therapy in Bangladesh indicates that cell therapy may be accomplished in general hospitals of developing countries if the proper design and mild to moderate types of invasive approach is utilized. The apparent safety of administered stem cells in LC patients and the observed effect on ascites of LC patients inspire optimism about the installation of new and innovative therapy in Bangladesh. Future studies with phase I/II may with stem cell and others cell may be planned at Bangladesh in patients with LC and other intractable diseases with suitable control arms.

PDF Share
  1. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319(17):1802-1813.
  2. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38 Suppl 1:2-6.
  3. Campana L, Iredale JP. Regression of Liver Fibrosis. Semin Liver Dis. 2017;37(1):1-10.
  4. Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol. 2015;21(17):5138-5148.
  5. Lanthier N, Lin-Marq N, Rubbia-Brandt L, Clément S, Goossens N, Spahr L. Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liverhistology and gene expression patterns?Stem Cell Res Ther. 2017;8(1):88.
  6. Fiore EJ, Domínguez LM, Bayo J, García MG, Mazzolini GD. Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies. World J Gastroenterol. 2018;24(23):2427-2440.
  7. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83.
  8. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420.
  9. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98.
  10. Saha BK, Mahtab MA, Akbar SMF, Noor-E-Alam SM, Mamun AA, Hossain SMS, Alam MA, Moben AL, Khondaker FA, Chowdhury FI, Raihan R, Rahman S, Choudhury AK; APASL ACLF working party. Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage. Hepatol Int. 2017;11(6):540-546.
  11. Al Mahtab M, Mn Alam S, L Moben A, Raihan R, A Alam M, A Rahim M. Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh. Euroasian J Hepatogastroenterol. 2017;7(1):113-115.
  12. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levièar N et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. The American journal of gastroenterology. 2008 Aug;103(8):1952-1958.
  13. Sellamuthu S, Manikandan R, Thiagarajan R, Babu G, Dinesh D, Prabhu D, et al. In vitro transdifferentiation of human umbilical cord derived hematopoietic stem cells into hepatocyte like cells using combination of growth factors for cell based therapy. Cytotechnology 2011;63:259-268.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.